Trump Announces 0% Tariffs on Generic Drugs for 2 Years, Then 100-200% Duties
UPSC / SSC current affairs note · Economy
Why in news
US President Donald Trump announced a two-year zero tariff on imported generic drugs starting August 1, followed by steep tariffs of 100-200% to boost domestic production. This policy directly impacts India, a major exporter of generic drugs to the US, and could reshape global pharmaceutical trade dynamics.
Background
The US is the largest market for Indian generic drugs, with India supplying about 40% of generic medicines consumed in the US. The announcement comes amid ongoing trade tensions and efforts by the US to reduce reliance on foreign pharmaceutical supply chains.
Key facts
US President Trump announced 0% tariffs on imported generic drugs for two years starting August 1.
After the two-year period, tariffs will increase to 100% and then 200% to encourage domestic production.
The policy aims to reduce US reliance on imported generic drugs and boost American manufacturing.
India is a leading exporter of generic drugs to the US, making this policy significant for Indian pharmaceutical companies.
The announcement is part of broader US trade policy shifts under the Trump administration.
The two-year zero tariff period may provide a temporary window for Indian exporters before higher duties take effect.
Prelims pointers
- US President: Donald Trump
- Policy: 0% tariff on generic drugs for 2 years from August 1, then 100-200% duties
- India's share of US generic drug market: ~40%
- Key Indian pharma exports to US: generic drugs
- Relevant body: US Trade Representative (USTR)
- Date: August 1 (start of zero tariff period)
Mains angles
- Impact on Indian pharmaceutical exports and trade balance with US
- Strategic implications for India's pharmaceutical industry and supply chain diversification
- Analysis of US protectionist trade policies and their effect on global trade norms
- Discussion on India's response and potential countermeasures or negotiations